Toshiki Etani

Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway

Keitaro Iida, Taku Naiki, Aya Naiki‐Ito et al. · Cancer Science · 2020 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16

GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer

Taku Naiki, Aya Naiki‐Ito, Makoto Asamoto et al. · Carcinogenesis · 2014 · 75 citations · Full text

Medicine, Molecular Biology, Oncology +16

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

Aya Naiki‐Ito, Taku Naiki, Hiroyuki Kato et al. · Carcinogenesis · 2019 · 56 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama et al. · The Lancet · 2025 · 47 citations · Full text

Medicine, Oncology, Urology +13

NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Toshiki Etani, Takayoshi Suzuki, Taku Naiki et al. · Oncotarget · 2014 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17